Diagnosis and management of HIV drug hypersensitivity

Journal of Allergy and Clinical Immunology

Volumn 121, Issue 4, 2008, Pages

  Davis, Carla M ^a   Shearer, William T ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

antiretroviral agents; drug hypersensitivity; fusion inhibitor; Human immunodeficiency virus; integrase inhibitor; protease inhibitor; trimethoprim sulfamethoxazole

Indexed keywords

ABACAVIR; AMPRENAVIR; AMPRENAVIR PHOSPHATE; ATAZANAVIR; COTRIMOXAZOLE; DARUNAVIR; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; ENFUVIRTIDE; FUSEON; INDINAVIR; ISONIAZID; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; PREDNISOLONE; PYRAZINAMIDE; RALTEGRAVIR; RIFAMPICIN; RITONAVIR; SAQUINAVIR; STAVUDINE; SULFONAMIDE; TENOFOVIR DISOPROXIL; TIPRANAVIR; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZALCITABINE; ZIDOVUDINE;

AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BLANCHING; CD4+ T LYMPHOCYTE; CHEST TIGHTNESS; CHILL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; COUGHING; DESENSITIZATION; DIARRHEA; DRUG DOSE INCREASE; DRUG ELIMINATION; DRUG ERUPTION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; DYSPNEA; ECZEMA; ERYTHEMA MULTIFORME; FATIGUE; FEVER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; IMMUNOHISTOCHEMISTRY; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE NODULE; JAUNDICE; LIVER TOXICITY; MACULAR EXANTHEMA; MACULOPAPULAR RASH; MALAISE; MYALGIA; NAUSEA; NEPHRITIS; NEUTROPENIA; PATCH TEST; PATIENT CARE; PHARYNGITIS; PNEUMOCYSTOSIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROPHYLAXIS; PRURITUS; RACE DIFFERENCE; RANDOMIZED CONTROLLED TRIAL; RASH; RHABDOMYOLYSIS; SIDE EFFECT; SKIN BIOPSY; SKIN MANIFESTATION; STEVENS JOHNSON SYNDROME; TACHYCARDIA; TACHYPNEA; THROMBOCYTOPENIA; TOXIC EPIDERMAL NECROLYSIS; TREATMENT DURATION; URTICARIA; VOMITING; WHEEZING;

EID: 41449111996     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaci.2007.10.021     Document Type: Article

References (60)

1. Pirmohamed M., and Park B. HIV and drug allergy. Curr Opin Allergy Clin Immunol 1 (2001) 311-316
2. Bacot B.K., Paul M.E., Navarro M., Abramson S.L., Kline M.W., Hanson I.C., et al. Objective measures of allergic disease in children with human immunodeficiency virus infection. J Allergy Clin Immunol 100 (1997) 707-711
3. Vilar F., Naisbitt D., Park B., and Pirmohamed M. Mechanisms of drug hypersensitivity in HIV infected patients: the role of the immune system. J HIV Ther 8 (2003) 42-47
4. Joint Task Force on Practice Parameters, the American Academy of Allergy, Asthma and Immunology, the American Academy of Allergy, Asthma and Immunology, and the Joint Council of Allergy, Asthma and Immunology. Executive summary of disease management of drug hypersensitivity: a practice parameter. Ann Allergy Asthma Immunol 83 (1999) 665-700
5. Gordin F.M., Simon G.L., Wofsy C.B., and Mills J. Adverse reactions to trimethoprim-sulfamethoxazole in patients with the acquired immunodeficiency syndrome. Ann Intern Med 100 (1984) 495-499
6. Kovacs J.A., Hiemenz J.W., Macher A.M., Stover D., Murray H.W., Shelhamer J., et al. Pneumocystis carinii pneumonia: a comparison between patients with the acquired immunodeficiency syndrome and patients with other immunodeficiencies. Ann Intern Med 100 (1984) 663-671
7. Shafer R.W., Seitzman P.A., and Tapper M.L. Successful prophylaxis of Pneumocystis carinii pneumonia with trimethoprim-sulfamethoxazole in AIDS patients with previous allergic reactions. J Acquir Immune Defic Syndr 2 (1989) 389-393
8. Reilly T.P., and Ju C. Mechanistic perspectives on sulfonamide-induced cutaneous drug reactions. Curr Opin Allergy Clin Immunol 2 (2002) 307-315
9. Carr A., Penny R., and Cooper D.A. Efficacy and safety of rechallenge with low-dose trimethoprim-sulphamethoxazole in previously hypersensitive HIV-infected patients. AIDS 7 (1993) 65-71
10. Carr A., Swanson C., Penny R., and Cooper D.A. Clinical and laboratory markers of hypersensitivity to trimethoprim-sulfamethoxazole in patients with Pneumocystis carinii pneumonia and AIDS. J Infect Dis 167 (1993) 180-185
11. Carr A., Gross A.S., Hoskins J.M., Penny R., and Cooper D.A. Acetylation phenotype and cutaneous hypersensitivity to trimethoprim-sulphamethoxazole in HIV infected patients. AIDS 8 (1994) 333-337
12. Hennessy S., Strom B.L., Berlin J.A., and Brennan P.J. Predicting cutaneous hypersensitivity reactions to cotrimoxazole in HIV infected individuals receiving primary Pneumocystis carinii pneumonia prophylaxis. J Gen Intern Med 10 (1995) 380-386
13. Walmsley S., Levinton C., Brunton J., Muradali D., Rappaport D., Bast M., et al. A multicenter randomized double blind placebo controlled trial of adjunctive corticosteroids in the treatment of Pneumocystis carinii pneumonia complication the acquired immune deficiency syndrome. J Acquir Immune Def Syndr Hum Reterovirol 8 (1995) 348-357
14. Yee D., Valiquette C., Pelletier M., Parisien I., Rocher I., and Menzies D. Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. Am J Respir Crit Care Med 167 (2003) 1472-1477
15. Pitche P., Mouzou T., Padonou C., and Tchangai-Walla K. Stevens-Johnson syndrome and toxic epidermal necrolysis after intake of rifampicin-isoniazid: report of 8 cases in HIV-infected patients in Togo. Med Trop (Mars) 65 (2005) 359-362
16. Neuman M.G., Malkiewicz I.M., Phillips E.J., Rachlis A.R., Ong D., Yeung E., et al. Monitoring adverse drug reactions to sulfonamide antibiotics in human immunodeficiency virus-infected individuals. Ther Drug Monit 24 (2002) 728-736
17. Koopmans P.P., and Burger D.M. Managing drug reactions to sulfonamides and other drug in HIV infection: desensitization rather than rechallenge. Pharm World Sci 20 (1998) 253-257
18. Cutrell A., Hernandez J., Fleming J., Edwards M., Moore M., Brothers C., et al. Updated clinical risk factor analysis of suspected hypersensitivity reactions to abacavir. Ann Pharmacother 38 (2004) 2171-2172
19. Symonds W., Cutrell A., Edwards M., Steel H., Spreen B., Powell G., et al. Risk factor analysis of hypersensitivity reactions to abacavir. Clin Ther 24 (2002) 565-573
20. Hervey P.S., and Perry C.M. Abacavir: a review of its clinical potential in patients with HIV infection. Drugs 60 (2000) 447-479
21. Hetherington S., McGuirk S., Powell G., Cutrell A., Naderer O., Spreen B., et al. Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir. Clin Ther 23 (2001) 1603-1614
22. Fontaine C., Guiard-Schmid J.B., Slama L., Essid A., Lukiana T., Rondeau E., et al. Severe rhabdomyolysis during a hypersensitivity reaction to abacavir in a patient treated with ciprofibrate. AIDS 19 (2005) 1927-1928
23. Escaut L., Liotier J.Y., Albengres E., Cheminot N., and Vittecoq D. Abacavir rechallenge has to be avoided in case of hypersensitivity reaction. AIDS 13 (1999) 1419-1420
24. Wit F.W.N.M., Wood R., Horban A., Beniowski M., Schmidt R.E., Gray G., et al. Prednisolone does not prevent hypersensitivity reactions in antiretroviral drug regimens containing abacavir with or without nevirapine. AIDS 15 (2001) 2423-2429
25. Phillips E.J., Sullivan J.R., Knowles S.R., and Shear N.H. Utility of patch testing in patients with hypersensitivity syndromes associated with abacavir. AIDS 16 (2002) 2223-2225
26. Thurmond L.M., Thorborn D., Ravitch J., Bazin C., Bouvet E., Hoen B., et al. Immunohistological characterization of skin rash observed in patients on abacavir who experience a hypersensitivity reaction. Antiretrovir Ther 5 (2000) 53
27. Phillips E.J., Wong G.A., Kaul R., Shahabi K., Nolan D.A., Knowles S.R., et al. Clinical and immunogenetic correlates of abacavir hypersensitivity. AIDS 19 (2005) 979-987
28. Easterbrook P.J., Waters A., Murad S., Ives N., Taylor C., King D., et al. Epidemiological risk factors for hypersensitivity reactions to abacavir. HIV Med 4 (2003) 321-324
29. Mallal S., Nolan D., Witt C., Masel G., Martin A.M., Moore C., et al. Association between presence of HLA-B*5701, HLA-DR7 and HLA-DQ3 and hypersensitivity to HIV-1 reverse transcriptase inhibitor abacavir. Lancet 359 (2002) 727-732
30. Hetherington S., Hughes A.R., Mosteller M., Shortino D., Baker K.L., Spreen W., et al. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet 359 (2002) 1121-1122
31. Rauch A., Nolan D., Martin A., McKinnon E., Almeida C., and Mallal S. Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV cohort study. Clin Infect Dis 43 (2006) 99-102
32. Phillips E.J. Genetic screening to prevent abacavir hypersensitivity reaction: are we there yet?. Clin Infect Dis 43 (2006) 103-105
33. Boehringer Ingelheim product insert. 2005. http://www.fda.gov/cder/foi/label/2005/20636s025,20933s014lbl.pdf. Accessed November 30, 2007.
34. Pollard R., Robinson P., and Dransfield K. Safety profile of nevirapine, a nonnucleoside reverse transcriptase inhibitor for the treatment of human immunodeficiency virus infection. Clin Ther 20 (1998) 1071-1092
35. Murphy R.L. Defining the toxicity profile of nevirapine and other antiretroviral drugs. J Acquir Immune Defic Syndr 34 (2003) S15-S20
36. Montaner J.S., Cahn P., Zala C., Casssetti L.I., Losso M., Hall D.B., et al. 1100.1286 Study Team. Randomized, controlled study of the effects of a short course of prednisone on the incidence of rash associated with nevirapine in patients infected with HIV-1. J Acquir Immune Defic Syndr 33 (2003) 41-46
37. Ho T.T., Wong K.H., Chan K.C., and Lee S.S. High incidence of nevirapine associated rash in HIV infected Chinese. AIDS 12 (1998) 2082-2083
38. Knobel H., Miro J.M., Domingo P., Rivero A., Marquez M., Force L., et al. GESIDA 09/99 Study Group. Failure of a short-term prednisone regimen to prevent nevirapine-associated rash: a double-blind placebo-controlled trial: the GESIDA 09/99 study. J Acquir Immune Defic Syndr 28 (2001) 14-18
39. Knobel H., Miro J.M., Mahillo B., Domingo P., Rivero A., Ribera E., et al. Grupo Estudio Syndrome Immunodeficiencies Adquirida 26/02 Study Group. Failure of cetirizine to prevent nevirapine-associated rash: a double-blind placebo-controlled trial for the GESIDA 26/01 Study. J Acquir Immune Defic Syndr 37 (2004) 1276-1281
40. Warren K., Boxwell D., Kim N., and Drolet B. Nevirapine-associated Stevens-Johnson syndrome. [letter]. Lancet 351 (1998) 561
41. Rotunda A., Hirsch R., Scheinfeld N., and Weinberg J. Severe cutaneous reactions associated with the use of human immunodeficiency virus medications. Acta Derm Venereol 83 (2003) 1-9
42. Rzany B., Mockenhaupt M., Stocker U., Hamouda O., and Schopf E. Incidence of Stevens Johnson syndrome and toxic epidermal necrolysis in patients with acquired immunodeficiency syndrome in Germany. Arch Dermatol 129 (1993) 1059
43. Roujeau J., and Stern R. Severe adverse cutaneous reactions to drugs. N Engl J Med 331 (1994) 1272-1285
44. Porteous D.M., and Berger T.G. Severe cutaneous drug reactions (Stevens-Johnson syndrome and toxic epidermal necrolysis) in human immunodeficiency virus infection. Arch Dermatol 127 (1991) 740-741
45. Phan T.G., Wong R.C., Crotty K., and Adelstein S. Toxic epidermal necrolysis in acquired immunodeficiency syndrome treated with intravenous gammaglobulin. Australas J Dermatol 40 (1999) 153-157
46. Claes P., Wintzen M., Allard S., Simons P., De Coninck A., and Lacor P. Nevirapine-induced toxic epidermal necrolysis and toxic hepatitis treated successfully with a combination of intravenous immunoglobulins and N-acetylcysteine. Eur J Intern Med 15 (2004) 255-258
47. Ogedegbe A.O., and Sulkowski M.S. Antiretroviral associated liver injury. Clin Liver Dis 7 (2003) 475-499
48. Drummond N.S., Vilar F.J., Naisbitt D.J., Hanson A., Woods A., Park B.K., et al. Drug specific T cells in an HIV positive patient with nevirapine induced hepatitis. Antivir Ther 11 (2006) 393-395
49. Martin A.M., Nolan D., James I., Cameron P., Keller J., Moore C., et al. Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T cell counts. AIDS 19 (2005) 97-99
50. DHHS Panel on Antivetroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. October 2006. http://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL.pdf. Accessed November 30, 2007.
51. Serious adverse events attributed to nevirapine regimens for post exposure prophylaxis after HIV exposures-worldwide, 1997-2000. Morbid Mortal Wkly Rep 49 (2001) 1153-1156
52. Herzmann C., Kinloch S., and Johnson M. Rash in an HIV positive patient. HIV Med 6 (2005) 379
53. Ouagari Z., Tubiana R., Mohand H.A., Dominguez S., Duvivier C., Bricaire F., et al. Skin rash associated with atazanavir: report of three cases. AIDS 20 (2006) 1207-1208
54. DeSimone J.A., Ojha A., Pathak R., and Cohn J. Successful desensitization to enfuvirtide after a hypersensitivity reaction in an HIV-1 infected man. Clin Infect Dis 39 (2004) 110-112
55. Ball R.A., Kinchelow T., and ISR Substudy Group. Injection site reactions with the HIV-1 fusion inhibitor enfurvirtide. J Am Acad Dermatol 49 (2003) 826-831
56. Lalezari J., Henry K., O'Hearn M., Montaner J.S., Piliero P.J., Trottier B., et al. TORO 1 Study Group. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med 348 (2003) 2175-2185
57. Shahar E., Moar C., and Pollack S. Successful desensitization of enfuvirtide induced skin hypersensitivity reaction. AIDS 19 (2005) 451-452
58. Clotet B., Raffi F., Cooper D., Delfraissy J.F., Lazzarin A., Moyle G., et al. Clinical management of treatment-experienced, HIV-infected patients with the fusion inhibitor enfuvirtide: consensus recommendations. AIDS 18 (2004) 1137-1146
59. Grinsztejn B., Nguyen B.Y., Katlama C., Gatell J.M., Lazzarin A., Vittecoq D., et al., Protocol 005 Team. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomized controlled trial. Lancet 369 (2007) 1261-1269
60. Naranjo C.A., Busto U., Sellers E.M., Sandor P., Ruiz I., Roberts E.A., et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 30 (1981) 239-245